bioAffinity Technologies, Inc. (BIAF) Stock

bioAffinity Technologies, Inc. (BIAF) is a Technology stock trading at $0.84 (as of 2026-06-18), with a market capitalization of $5.31M and a trailing P/E of -0.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

bioAffinity Technologies, Inc. is a biotechnology company developing non-invasive diagnostic tests and targeted cancer therapeutics. Its CyPath lung diagnostic test is designed for early detection of lung cancer, and it conducts research into targeted cancer therapies.

Valuation — source: SEC EDGAR (first-party)

Price	$0.84
Market Cap	$5.31M
P/E Ratio	-0.1
EV / EBITDA	-0.1
Price / Book	1.04
Price / Sales	0.67
DCF Value (model)	$-34.13
DCF Upside vs Price	-4143.8%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$6.16M
Net Margin	-242.0%
Return on Equity	-433.7%
Debt / Equity	0.07
Current Ratio	1.36
Revenue Growth (YoY)	-27.1%
EPS Growth (YoY)	406.3%
FCF Growth (YoY)	91.0%

Financial Health — source: SEC EDGAR

Altman Z-Score

-9.87 (distress)

Valuation vs Sector & Industry

Stock P/E	-0.1
Sector P/E (Technology)	32.6
Industry P/E (Business Services)	27.1
vs Sector	-100.3%
vs Industry	-100.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	VANGUARD CAPITAL MANAGEMENT LLC ($212730.00)
Institutional Holders Tracked	10

Company

Sector	Technology
Industry	Business Services
CEO	Maria Zannes
Employees	57
Country	US
IPO Date	2022-09-01

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

• Q/C Technologies, Inc. (QCLS)
• Advanced Biomed Inc. Common Stock (ADVB)
• American Shared Hospital Services (AMS)
• BioNexus Gene Lab Corp. (BGLC)
• Biomerica, Inc. (BMRA)
• Cardio Diagnostics Holdings, Inc. (CDIO)
• Aclarion, Inc. (ACON)
• iSpecimen Inc. (ISPC)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.